Bio-Rad Laboratories, Inc. (BIO) Stock Forecast Oct. 16, 2026
Analysis updated on Oct. 16, 2026 (UTC) · Total · absolute moveSwitch to Alpha · NYSE
Bio-Rad Laboratories, Inc. (BIO) stock forecast summary
Our AI ranks Bio-Rad Laboratories, Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
Bio-Rad Laboratories, Inc. is a mid-cap company with a market capitalization of $9.46B. It ranks number 7 by market capitalization among the 25 Laboratory Analytical Instruments issuers in our coverage with a current forecast.
For BIO, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 53.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 37.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected absolute price move over the horizon, market included. This is the number a price target is built from. Ratings: strong buy ≥ +5.0%, buy ≥ +3.4%, sell < +1.8%, strong sell < +0.8% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-16 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, BIO included.
Follow BIO freeBIO price chart and AI forecast
How BIO ranks among 5171 stocks
90D Total forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Bio-Rad Laboratories, Inc. (BIO) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Laboratory Analytical Instruments peers listed below that report each metric.
Valuation & Market
| Metric | BIO | Rank |
|---|---|---|
| Market Cap | $9.46B | 7/25 |
| P/E Ratio | 43.18x | 5/7 |
| P/B Ratio | 1.32x | 18/23 |
| EPS | $8.19 | – |
| Book Value/Share | $268.30 | – |
| Revenue/Share | $96.84 | – |
| FCF/Share | $13.21 | – |
Profitability & Margins
| Metric | BIO | Rank |
|---|---|---|
| ROE | 3.1% | 5/20 |
| ROA | 2.2% | 4/20 |
| ROIC | 0.6% | 5/20 |
| Gross Margin | 51.9% | 9/19 |
| Operating Margin | 2.0% | 5/21 |
| Net Margin | 8.6% | 4/19 |
| EBT Margin | 13.5% | 4/22 |
| Tax Rate | 36.5% | – |
Financial Health
| Metric | BIO | Rank |
|---|---|---|
| Current Ratio | 3.14x | 13/25 |
| Quick Ratio | 2.33x | 12/24 |
| D/E Ratio | 0.43x | 14/24 |
| Financial Leverage | 1.43x | 14/23 |
| Interest Coverage | 6.0x | 3/21 |
| Working Capital | $2.06B | 3/25 |
Cash Flow
| Metric | BIO | Rank |
|---|---|---|
| Operating Cash Flow | $493M | 7/24 |
| Free Cash Flow | $353M | 6/20 |
| Capital Spending | -$140M | 18/20 |
| OCF Growth YoY | -7.8% | 8/12 |
| FCF Growth YoY | -4.8% | 7/11 |
| FCF/Sales | 13.6% | 6/19 |
| CapEx/Sales | 5.4% | 3/19 |
Operational Efficiency
| Metric | BIO | Rank |
|---|---|---|
| Asset Turnover | 0.25x | 16/20 |
| Receivables Turnover | 5.9x | 11/19 |
| Inventory Turnover | 1.6x | 16/19 |
| Fixed Assets Turnover | 5.0x | 10/21 |
| Days Sales Outstanding | 62 days | 9/19 |
| Days Inventory | 229 days | 4/19 |
| Payables Period | 42 days | 11/18 |
| Cash Conversion Cycle | 249 days | 3/17 |
Income Statement
| Metric | BIO | Rank |
|---|---|---|
| Total Revenue | $2.59B | 8/21 |
| Operating Income | $53M | 5/21 |
| Net Income | $222M | 5/21 |
| R&D Expense | $266M | 5/21 |
| SG&A Expense | $852M | 8/20 |
| Cost of Goods Sold | $1.25B | 7/19 |
Dividend & Shareholder Information
| Metric | BIO | Rank |
|---|---|---|
| Shares Outstanding | 27M | – |
| Net Income Growth | -30.3% | 4/7 |
| EPS Growth | -84.0% | 6/8 |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $3.02B | 29.5% of assets |
| Cash & Short-term Investments | $517M | 5.0% of assets |
| Accounts Receivable | $442M | 4.3% of assets |
| Inventory | $781M | 7.6% of assets |
| Total Liabilities | $3.08B | 30.0% of assets |
| Short-term Debt | $818M | 8.0% of assets |
BIO quarterly financials and insider trading
Bio-Rad Laboratories, Inc. (BIO) industry peers
Companies classified under the same SEC industry code as Bio-Rad Laboratories, Inc. (Laboratory Analytical Instruments): 25 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Total) | Market Cap |
|---|---|---|
| BIO Bio-Rad Laboratories, Inc. | ▼ | $9.46B |
| A Agilent Technologies, Inc. | ▼ | $48.75B |
| WAT Waters Corp /De/ | ▶ | $43.64B |
| ILMN Illumina, Inc. | ▲ | $39.64B |
| MTD Mettler Toledo International Inc/ | ▼ | $32.51B |
| RVTY Revvity, Inc. | ▶ | $17.03B |
| AVTR Avantor, Inc. | ▼ | $11.19B |
| TXG 10x Genomics, Inc. | ▲ | $9.10B |
| BRKR Bruker Corp | ▲ | $8.35B |
| ALMR Alamar Biosciences, Inc. | ▲ | $1.75B |
| CTKB Cytek Biosciences, Inc. | ▲ | $682M |
| PACB Pacific Biosciences Of California, Inc. | ▲ | $538M |
| MASS 908 Devices Inc. | ▲ | $465M |
| NAUT Nautilus Biotechnology, Inc. | ▲ | $262M |
| EYPT Eyepoint, Inc. | ▲ | $258M |
| BFNH Bioforce Nanosciences Holdings, Inc. | ▼ | $221M |
| QTRX Quanterix Corp | ▲ | $136M |
| SEER Seer, Inc. | ▲ | $113M |
| RPID Rapid Micro Biosystems, Inc. | ▲ | $42M |
| PRPO Precipio, Inc. | ▶ | $38M |
| HBIO Harvard Bioscience Inc | ▼ | $38M |
| BNGO Bionano Genomics, Inc. | ▲ | $16M |
| LCTC Lifeloc Technologies, Inc | ▲ | $11M |
| ASTC Astrotech Corp | ▲ | $10M |
| SCND Scientific Industries Inc | ▶ | $8M |
Where BIO sits on the market map
Bio-Rad Laboratories, Inc. (BIO) stock news
Loading...
Bio-Rad Laboratories, Inc. (BIO) stock forecast FAQ
What is the Bio-Rad Laboratories, Inc. (BIO) stock forecast?
Our AI ranks Bio-Rad Laboratories, Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
How accurate are Bio-Rad Laboratories, Inc. stock predictions?
For BIO, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 53.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 37.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Bio-Rad Laboratories, Inc. forecasts updated?
Bio-Rad Laboratories, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 16, 2026.
Which companies are Bio-Rad Laboratories, Inc.'s industry peers?
25 issuers in our coverage, BIO included, share the SEC industry code Laboratory Analytical Instruments. The largest are: Agilent Technologies, Inc. (A), Waters Corp /De/ (WAT), Illumina, Inc. (ILMN), Mettler Toledo International Inc/ (MTD), Revvity, Inc. (RVTY), Avantor, Inc. (AVTR).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.